Novel MAO-B Antagonist for Parkinson’s Disease

About the Asset

Monoamine oxidase-B (MAO-B) is a well-validated drug target for Parkinson’s disease, playing a central role in L-dopamine regulation and homeostasis in the brain. Global demand for MAO-B inhibitors continues to grow as the prevalence of Parkinson’s increases with aging populations.

Using an iterative fragment-based design strategy, we designed and optimized a novel small molecule for binding into the MAO-B catalytic domain. Its docking behavior (binding energies and predicted dissociation constants) was compared against known experimental and FDA-approved MAO-B inhibitors.

Performance Prospectus

Comparative performance metrics are summarized in a concise one-page prospectus. Note: The drug structure is not disclosed in the prospectus—only comparative results. The full structure and all raw supporting data are released exclusively to the buyer after payment confirmation.

📄

Download 1-Page Prospectus (PDF)

Comparative docking, MD stability, and ADMET summary — structure withheld until purchase

What the Buyer Receives

Upon purchase, the client receives the following in confidence:

• Fully executed exclusive sales agreement describing the IP, conveyance method, price/terms, payment method, and non-disclosure conditions.
• Complete drug prospectus summarizing in-silico performance versus experimental and FDA-approved MAO-B inhibitors (docking, MD stability, ADMET).
• Drug molecular structure including electronic properties, tautomers, chirality, etc.
• All supporting raw data used to generate the prospectus, including MD trajectories (GROMACS XTC, AMBER, Yasara, or PDB formats).
• Description of the non-proprietary methods and strategies used to generate the IP.
• Up to 16 hours of consulting support at 50% of normal rates for IP transition, further optimization, or similarity searching.
• Option for additional unlimited consulting at standard rates for extended MD, deep similarity searching, VLS, and related studies.